Analysis of the two main TGFβ1 receptors in tissue samples of adenomas and adenocarcinomas.

<p>TGFβ1RI: TGFβ1 receptor I; TGFβ1RII: TGFβ1 receptor II.</p><p>TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma.</p><p>In brackets percentages of patients with alteration of the TGFβ1 receptor system. Minimal or low grade immunostaining was taken as an index of receptors’alteration.</p

Evaluation of serum levels of IL-8 and IL-6 during colorectal carcinogenesis.

<p>The levels of IL-8 (A) and IL-6 (B) were measured in controls and patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma). IL-8 and IL-6 were detected by ELISA and values expressed as pg/ml serum (see materials and methods). A: dots correspond to IL-8 single values and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 17.0±2.5; TA 15.9±3.7; TVA 18.4±2.2; IAC 25.4±4.8; IIAC 38.7±5.1; IIIAC 37.2±5.7; IVAC 30.5±5.7. *Significantly different versus control group (p<0.05). B: dots correspond to single IL-6 values and black lines represent the mean values within experimental groups. Mean values ± SEM: N 247.1±55; TA 375.9±54; TVA 407.9±80; IAC 237.9±68; IIAC 472.3±89; IIIAC 521.3±152; IVAC 436.3±118. *Significantly different versus control group (p<0.05).</p

Evaluation of serum levels of TGFβ1 and VEGF during colorectal carcinogenesis.

<p>The levels of TGFβ1 (A) and VEGF (B) were measured in controls and patient groups (N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma). TGFβ1 and VEGF were detected by ELISA and values expressed as ng/ml and pg/ml serum, respectively (see materials and methods). A: dots correspond to single TGFβ1 values and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 6.3±0.4; TA 7.2±0.45; TVA 6.3±0.6; IAC 6.9±0.3; IIAC 4.9±0.3; IIIAC 4.4±0.3; IVAC 5.7±0.5. *Significantly different versus control group (p<0.05). B: dots correspond to single VEGF values and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 227.0±18.7; TA 215.2±31.3; TVA 221.1±36.4; IAC 216.3±34.4; IIAC 205.0±26.6; IIIAC 266.5±38.6; IVAC 295.2±70.2.</p

Distribution and expression of MMP-9 on paraffin embedded CRC tissue sections.

<p>A: a representative image of carcinoma tissue at stage III showed strong staining for MMP-9, localized in the cytoplasm of both tumor cells and inflammatory cells (10x/0.22 objective). For experimental details see materials and methods. B: higher magnification of a MMP-9 positive area of the same cancer section (40x/0.65 objective). The images were obtained using Digital Microscope DMD Leica, Leica Microsystems, Milan, Italy.</p

Determination and Comparison of the <i>Francisella tularensis</i> subsp.<i>novicida</i> U112 Proteome to Other Bacterial Proteomes

The proteins expressed by Francisella tularensis subsp. novicida U112 grown to midexponential phase were surveyed by nanoLC-tandem mass spectrometry (LC-MS/MS). To improve annotation of the genome and develop a technology to provide high-throughput analysis of the Francisella proteome in multiple conditions, we sought to establish a fast and simple analysis that would reduce as much as possible the false discovery rate. Our survey detected expression of 63.0% of the predicted proteome from the stable condition of growth in rich medium available at (www.francisella.org). On the basis of detection of essential proteins, we estimated coverage to be approximately 80% of the actual expressed proteome. This suggests that no less than 70% of the proteins could be expressed in this condition. This analysis revealed two previously unidentified protein coding open reading frames and validated 50% of the proteins annotated as hypothetical. On the basis of results of the screen to detect essential proteins, not all proteins expressed provide a measurable contribution to F.t. novicida growth in this condition. Comparison of this protein profile with other profiles previously published suggested that the genome size and number of genes involved in regulation have little effect on the number of proteins expressed in a given stable condition

Effect of oxysterols on COX-2 synthesis and mPGES-1 expression.

<p>(A) SH-SY5Y cells were treated for 48 h with 5 µM 7β-hydroxycholesterol (7β-OH), 24-hydroxycholesterol (24-OH), 27-hydroxycholesterol (27-OH) or 15 µM oxysterol mixture (Mix). Untreated cells (Control) were taken as controls. COX-2 levels were analyzed by Western blotting. Top: blot representative of three experiments. Bottom: histogram representing mean values ± SD of three experiments. COX-2 densitometric measurements were normalized against the corresponding actin levels and expressed as percentages of control value.**P<0.01 and ***P<0.001 vs. control. (B) mPGES-1 expression was quantified by real-time RT-PCR in SH-SY5Y cells treated for 6 h with 5 µM 7β-OH, 24-OH, 27-OH or 15 µM oxysterol mixture. Some cells were pretreated for 1 h with 5 µM free quercetin (Q_F) or with 5 µM quercetin loaded into nanoparticles (Q_N) before oxysterol treatment. Untreated cells (Control) were taken as controls. Data, normalized to β₂-microglobulin, are expressed as mean values ± SD of three different experiments. ***P<0.001 vs. control; ###P<0.001 vs. specific oxysterol.</p

Average diameter, polydispersity index and zeta potential of the nanoparticle formulations.

<p>Average diameter, polydispersity index and zeta potential of the nanoparticle formulations.</p

Image1.TIF

<p>Francisella tularensis is a highly infectious Gram-negative bacterium that is the etiologic agent of tularemia in animals and humans and a Tier 1 select agent. The natural incidence of pneumonic tularemia worldwide is very low; therefore, it is not feasible to conduct clinical efficacy testing of tularemia medical countermeasures (MCM) in human populations. Development and licensure of tularemia therapeutics and vaccines need to occur under the Food and Drug Administration's (FDA's) Animal Rule under which efficacy studies are conducted in well-characterized animal models that reflect the pathophysiology of human disease. The Tularemia Animal Model Qualification (AMQ) Working Group is seeking qualification of the cynomolgus macaque (Macaca fascicularis) model of pneumonic tularemia under Drug Development Tools Qualification Programs with the FDA based upon the results of studies described in this manuscript. Analysis of data on survival, average time to death, average time to fever onset, average interval between fever and death, and bacteremia; together with summaries of clinical signs, necropsy findings, and histopathology from the animals exposed to aerosolized F. tularensis Schu S4 in five natural history studies and one antibiotic efficacy study form the basis for the proposed cynomolgus macaque model. Results support the conclusion that signs of pneumonic tularemia in cynomolgus macaques exposed to 300–3,000 colony forming units (cfu) aerosolized F. tularensis Schu S4, under the conditions described herein, and human pneumonic tularemia cases are highly similar. Animal age, weight, and sex of animals challenged with 300–3,000 cfu Schu S4 did not impact fever onset in studies described herein. This study summarizes critical parameters and endpoints of a well-characterized cynomolgus macaque model of pneumonic tularemia and demonstrates this model is appropriate for qualification, and for testing efficacy of tularemia therapeutics under Animal Rule.</p

Evaluation of serum MMP activity and levels during colorectal carcinogenesis.

<p>A: active forms of MMP-2 and MMP-9 are shown in a representative gelatin zymography. B: MMP-9 activation in the serum was evaluated by densitometric analysis as percentage of active MMP-9 compared to controls (taken as 100%). Dots correspond to the activated MMP-9 value for each subject and black lines represent mean values within the experimental groups. Mean values ± SEM: TA 120±3.9; TVA 121±8.5; IAC 151.63±17.2; IIAC 163.81±16.6; IIIAC 164.2±10.6; IVAC 129.0±13.0. *Significantly different versus control group (p<0.01). C: serum levels of MMP-9 protein were detected by ELISA and expressed as ng/ml serum. Dots correspond to the MMP-9 value for each subject and black lines represent the mean values within the experimental groups. Mean values ± SEM: N 1.5±0.2; TA 1.9±0.3; TVA 1.9±0.3; I AC 2.7±0.3; IIAC 2.8±0.3; IIIAC 3.0±0.5; IVAC 2.6±0.4. *Significantly different versus control group (p<0.05). N: control; TA: tubular adenoma; TVA: tubulovillous adenoma; I-IV AC: malignant stages of adenocarcinoma.</p

Cell viability and cell uptake of β-CD-dodecylcarbonate nanoparticles.

<p>A) SH-SY5Y cells were incubated with β-CD-dodecylcarbonate nanoparticles with (Q_N) or without (NPs) being loaded with quercetin (5 µM). Some cells were treated with 5 µM quercetin alone (Q_F). Untreated cells (Control) were taken as controls. Cell viability was measured in terms of release of the enzyme lactate dehydrogenase (LDH), as described in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0096795#s2" target="_blank">Materials and Methods</a> section. Data represent the mean values ± SD of three different experiments. B) SH-SY5Y cells were incubated with fluorescent coumarin 6-β-CD-dodecylcarbonate nanoparticles for the times indicated and then analyzed by confocal laser scanning microscopy (40X/0.75).</p